Teva Pharmaceutical Industries (NYSE:TEVA) Lowered to “Sell” at ValuEngine

ValuEngine downgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a hold rating to a sell rating in a research report report published on Thursday, ValuEngine reports.

Other analysts have also recently issued reports about the stock. Oppenheimer set a $12.00 target price on shares of Teva Pharmaceutical Industries and gave the company a buy rating in a report on Wednesday, June 12th. Royal Bank of Canada set a $19.00 target price on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a report on Friday, May 3rd. Morgan Stanley cut shares of Teva Pharmaceutical Industries from an equal weight rating to an underweight rating and reduced their price objective for the stock from $16.00 to $6.00 in a research note on Monday, July 15th. Credit Suisse Group reissued a neutral rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, July 10th. Finally, Wolfe Research assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, July 19th. They issued a peer perform rating and a $9.00 price objective for the company. Six equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Teva Pharmaceutical Industries has an average rating of Hold and an average price target of $15.13.

TEVA stock traded up $0.03 during midday trading on Thursday, reaching $7.86. 10,377,281 shares of the company’s stock traded hands, compared to its average volume of 18,220,274. Teva Pharmaceutical Industries has a 52-week low of $7.46 and a 52-week high of $25.96. The company has a market cap of $8.06 billion, a PE ratio of 2.81, a P/E/G ratio of 0.83 and a beta of 1.64. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.66. The stock’s 50-day moving average is $8.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, May 2nd. The company reported $0.57 EPS for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The business had revenue of $4.30 billion during the quarter, compared to analysts’ expectations of $4.38 billion. During the same period in the prior year, the company earned $0.94 earnings per share. The firm’s revenue was down 15.2% on a year-over-year basis. Sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.26 earnings per share for the current fiscal year.

In related news, Director Sol J. Barer bought 111,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was bought at an average cost of $8.98 per share, with a total value of $996,780.00. Following the completion of the purchase, the director now owns 115,942 shares of the company’s stock, valued at approximately $1,041,159.16. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Notaristefani Carlo De sold 16,070 shares of the firm’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $11.42, for a total transaction of $183,519.40. Following the transaction, the vice president now directly owns 49,659 shares of the company’s stock, valued at $567,105.78. The disclosure for this sale can be found here. Company insiders own 0.49% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of TEVA. Kavar Capital Partners LLC bought a new position in Teva Pharmaceutical Industries during the second quarter valued at $35,000. G&S Capital LLC lifted its position in Teva Pharmaceutical Industries by 99.4% during the second quarter. G&S Capital LLC now owns 4,012 shares of the company’s stock valued at $37,000 after purchasing an additional 2,000 shares during the last quarter. Lindbrook Capital LLC lifted its position in Teva Pharmaceutical Industries by 61.2% during the first quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock valued at $39,000 after purchasing an additional 945 shares during the last quarter. NEXT Financial Group Inc lifted its position in Teva Pharmaceutical Industries by 384.8% during the second quarter. NEXT Financial Group Inc now owns 4,276 shares of the company’s stock valued at $39,000 after purchasing an additional 3,394 shares during the last quarter. Finally, Cullen Frost Bankers Inc. bought a new position in Teva Pharmaceutical Industries during the first quarter valued at $40,000. 65.48% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

See Also: Dividend Achievers

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.